JP5090423B2 - モルホリノプリン誘導体 - Google Patents

モルホリノプリン誘導体 Download PDF

Info

Publication number
JP5090423B2
JP5090423B2 JP2009236444A JP2009236444A JP5090423B2 JP 5090423 B2 JP5090423 B2 JP 5090423B2 JP 2009236444 A JP2009236444 A JP 2009236444A JP 2009236444 A JP2009236444 A JP 2009236444A JP 5090423 B2 JP5090423 B2 JP 5090423B2
Authority
JP
Japan
Prior art keywords
group
substituents selected
alkylamino
mmol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009236444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011001339A5 (enExample
JP2011001339A (ja
Inventor
清 中山
和幸 杉田
正樹 瀬戸口
裕一 冨永
正規 齋藤
高志 小田桐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2009236444A priority Critical patent/JP5090423B2/ja
Publication of JP2011001339A publication Critical patent/JP2011001339A/ja
Publication of JP2011001339A5 publication Critical patent/JP2011001339A5/ja
Application granted granted Critical
Publication of JP5090423B2 publication Critical patent/JP5090423B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009236444A 2008-10-14 2009-10-13 モルホリノプリン誘導体 Expired - Fee Related JP5090423B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009236444A JP5090423B2 (ja) 2008-10-14 2009-10-13 モルホリノプリン誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008264797 2008-10-14
JP2008264797 2008-10-14
JP2009121690 2009-05-20
JP2009121690 2009-05-20
JP2009236444A JP5090423B2 (ja) 2008-10-14 2009-10-13 モルホリノプリン誘導体

Publications (3)

Publication Number Publication Date
JP2011001339A JP2011001339A (ja) 2011-01-06
JP2011001339A5 JP2011001339A5 (enExample) 2012-09-20
JP5090423B2 true JP5090423B2 (ja) 2012-12-05

Family

ID=42106564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009236444A Expired - Fee Related JP5090423B2 (ja) 2008-10-14 2009-10-13 モルホリノプリン誘導体

Country Status (21)

Country Link
US (2) US8097622B2 (enExample)
EP (1) EP2336132B1 (enExample)
JP (1) JP5090423B2 (enExample)
KR (1) KR101614976B1 (enExample)
CN (1) CN102245607B (enExample)
AU (1) AU2009304789B2 (enExample)
BR (1) BRPI0920199A2 (enExample)
CA (1) CA2740471C (enExample)
CO (1) CO6362009A2 (enExample)
DK (1) DK2336132T3 (enExample)
ES (1) ES2452541T3 (enExample)
IL (1) IL212278A (enExample)
MX (1) MX2011003490A (enExample)
MY (1) MY156456A (enExample)
NZ (1) NZ592761A (enExample)
PL (1) PL2336132T3 (enExample)
PT (1) PT2336132E (enExample)
RU (1) RU2490269C2 (enExample)
TW (1) TWI378933B (enExample)
WO (1) WO2010044401A1 (enExample)
ZA (1) ZA201102449B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
WO2011058027A2 (en) * 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
CN102260263A (zh) * 2010-05-26 2011-11-30 四川大学 一类二苯胺基嘌呤衍生物及制备方法和医药用途
MX2013000389A (es) 2010-07-14 2013-03-08 Hoffmann La Roche Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
EA026134B1 (ru) 2010-12-16 2017-03-31 Ф. Хоффманн-Ля Рош Аг Трициклические ингибиторы pi3k и способы их применения
SG11201401716XA (en) 2011-10-28 2014-05-29 Novartis Ag Novel purine derivatives and their use in the treatment of disease
CN103012284A (zh) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 一种2-氨基-5-溴嘧啶类化合物的制备方法
TW201520215A (zh) * 2013-05-13 2015-06-01 Daiichi Sankyo Co Ltd Ｎ－□啉基嘌呤衍生物之製造方法
TW201521791A (zh) * 2013-05-13 2015-06-16 Daiichi Sankyo Co Ltd ５－｛８－［（３ｒ）－４－乙醯基－３－甲基哌－１－基］－６－□啉－４－基－９－（２，２，２－三氟乙基）－９ｈ－嘌呤－２－基｝嘧啶－２－胺、及其藥理容許鹽之新穎結晶、及其製造方法
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
AU2014331049B2 (en) * 2013-10-04 2018-03-29 Torqur Ag Conformationally restricted PI3K and mTOR inhibitors
TR201910941T4 (tr) 2015-03-30 2019-08-21 Daiichi Sankyo Co Ltd 6-morfolinil-2-pirazolil-9H-pürin deriveleri ve PI3K inhibitörleri olarak kullanımları.
WO2017136689A1 (en) * 2016-02-05 2017-08-10 Academia Sinica Purine compounds possessing anticancer activity
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CA3045596C (en) 2016-12-02 2022-08-23 Daiichi Sankyo Company, Limited Endo-.beta.-n-acetylglucosaminidase
EP3360865A1 (en) 2017-02-13 2018-08-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of cyclopropyldiketopiperazines, and of a key intermediate of ds-5272
TWI837231B (zh) 2018-11-29 2024-04-01 日商第一三共股份有限公司 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途
CN113368114B (zh) * 2020-03-10 2022-04-22 四川大学 一种吗啉嘧啶类化合物的抗肿瘤应用
JP2024511996A (ja) * 2021-03-17 2024-03-18 タンゴ セラピューティクス， インコーポレイテッド 抗がん剤としてのプリン誘導体

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864145A (en) * 1959-06-02 1961-03-29 Thomae Gmbh Dr K Novel purines and a process for their manufacture
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3810017B2 (ja) 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
KR101046015B1 (ko) 2002-10-25 2011-07-01 젠야쿠코교가부시키가이샤 헤테로고리 화합물 및 이것을 유효성분으로 하는 항종양제
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
DK2316831T3 (da) 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
HRP20130902T1 (hr) 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
PT1940839E (pt) 2005-10-07 2013-10-10 Exelixis Inc Inibidores de piridopirimidinona pi3k alfa
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
KR20090021155A (ko) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
PL2041139T3 (pl) 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
GB0611152D0 (en) 2006-06-06 2006-07-19 Ucb Sa Therapeutic agents
AU2007282535B9 (en) 2006-08-08 2013-06-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as PI3K inhibitor and use thereof
JP5227321B2 (ja) 2006-08-23 2013-07-03 クドス ファーマシューティカルズ リミテッド Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
WO2008023159A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20090325957A1 (en) 2006-08-24 2009-12-31 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CN101563339A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CN101563340A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
EP2061784A1 (en) 2006-09-14 2009-05-27 AstraZeneca AB 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
EP2097405A2 (en) 2006-11-21 2009-09-09 Smithkline Beecham Corporation Anti-viral compounds
CA2671845C (en) 2006-12-07 2015-03-24 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
CA2675558A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
JP2010523637A (ja) 2007-04-12 2010-07-15 エフ．ホフマン−ラ ロシュ アーゲー 医薬化合物
US20100130496A1 (en) 2007-04-12 2010-05-27 F. Hoffmann-La Roche Ag Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
GB0707087D0 (en) 2007-04-12 2007-05-23 Piramed Ltd Pharmaceutical compounds
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
ATE510841T1 (de) 2007-06-12 2011-06-15 Hoffmann La Roche Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
EP2207555B1 (en) 2007-10-05 2013-07-24 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
ES2406129T3 (es) 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina
US8129371B2 (en) 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
JP5638955B2 (ja) 2007-10-26 2014-12-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
US20090149458A1 (en) 2007-11-27 2009-06-11 Wyeth PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS
GB0723748D0 (en) 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
WO2009071895A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009071890A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
GB0723747D0 (en) 2007-12-04 2008-12-31 Ucb Pharma Sa Therapeutic agents
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
MX2010007746A (es) 2008-01-15 2010-08-18 Wyeth Llc Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis.
WO2009093981A1 (en) 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US8557807B2 (en) 2008-01-24 2013-10-15 Signal Rx Pharmaceuticals, Inc. Thienopyranones as kinase inhibitors
JP2011510071A (ja) 2008-01-25 2011-03-31 アストラゼネカ アクチボラグ 鏡像異性的に純粋な（−）２−［１−（７−メチル−２−（モルホリン−４−イル）−４−オキソ−４Ｈ−ピリド［１，２−ａ］ピリミジン−９−イル）エチルアミノ］安息香酸、医学的療法における該物質の使用、および該物質を含む薬学的組成物−０２６
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives

Also Published As

Publication number Publication date
PL2336132T3 (pl) 2014-06-30
RU2011119525A (ru) 2012-11-27
CN102245607A (zh) 2011-11-16
CA2740471A1 (en) 2010-04-22
IL212278A (en) 2016-07-31
DK2336132T3 (da) 2014-04-07
RU2490269C2 (ru) 2013-08-20
NZ592761A (en) 2012-05-25
US20100130492A1 (en) 2010-05-27
JP2011001339A (ja) 2011-01-06
CA2740471C (en) 2013-09-17
MY156456A (en) 2016-02-26
EP2336132B1 (en) 2014-01-01
US20120071476A1 (en) 2012-03-22
ES2452541T3 (es) 2014-04-01
US8097622B2 (en) 2012-01-17
BRPI0920199A2 (pt) 2019-09-24
WO2010044401A1 (ja) 2010-04-22
EP2336132A1 (en) 2011-06-22
CO6362009A2 (es) 2012-01-20
TW201018690A (en) 2010-05-16
PT2336132E (pt) 2014-04-02
CN102245607B (zh) 2014-07-02
KR20110067038A (ko) 2011-06-20
KR101614976B1 (ko) 2016-04-22
ZA201102449B (en) 2011-12-28
AU2009304789A1 (en) 2010-04-22
MX2011003490A (es) 2011-04-21
HK1158189A1 (en) 2012-07-13
EP2336132A4 (en) 2012-03-21
IL212278A0 (en) 2011-06-30
AU2009304789B2 (en) 2012-04-05
TWI378933B (en) 2012-12-11
US8309546B2 (en) 2012-11-13

Similar Documents

Publication Publication Date Title
RU2490269C2 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПУРИНА, ОБЛАДАЮЩИЕ PI3K И/ИЛИ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ
EP4549439A1 (en) Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof
EP3733663B1 (en) 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer
EP4026832A1 (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7
SG185617A1 (en) Purinone derivative
EP2483272A2 (en) Pi3k (delta) selective inhibitors
WO2010005558A2 (en) Pi3k isoform selective inhibitors
EP2571884A2 (en) Mtor selective kinase inhibitors
JP2022529152A (ja) Ｃｄ７３阻害剤
EP3546458A1 (en) Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
JP2011236198A (ja) モルホリノプリン誘導体
EP2065388B1 (en) Pyrazolopyrimidine derivative
JP2025519493A (ja) Ｄｇｋ阻害剤としての三環式トリアゾロ化合物
JP5565913B2 (ja) 三環性ピラゾロピリミジン誘導体
RS59213B1 (sr) 6-morfolinil-2-pirazolil-9h-purinski derivati i njihova primena kao pi3k inhibitora
HK1158189B (en) Morpholinopurine derivative
TW202204365A (zh) 作為用於治療癌症之ent抑制劑之巨環二胺衍生物及其與腺苷受體拮抗劑之組合
JP2012067087A (ja) 三環性ピラゾロピリミジン誘導体
HK40040029A (en) 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer
HK40040029B (en) 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer
HK1164308A (en) Tricyclic pyrazolopyrimidine derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120807

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20120807

TRDD Decision of grant or rejection written
A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120829

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120903

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120912

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150921

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5090423

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees